Hepatiq Inc.

Irvine,  CA 
United States
http://www.hepatiq.com

• Booth: 2097

HEPATIQ is the only test quantifying liver function. All other tests estimate liver fibrosis. Function outperforms fibrosis in predicting outcomes.

HEPATIQ quantifies liver function by analyzing SPECT images.  Liver function can be reduced by infections, alcohol and fat buildup.  The liver can regenerate new functioning nodules, and blood flow to the liver may increase to get more function from the remaining nodules. 

Biopsies, elastography and blood tests estimate liver fibrosis.  Patient outcomes are determined by residual liver function, not the extent of fibrosis.  This was established in the 8 year, prospective, multi-center, NIH sponsored HALT-C trial. Subsequent research has further confirmed that function outperforms fibrosis in predicting outcomes.

The HEPATIQ report shows six indices: PHM (liver function), fLV (liver volume), fSV (spleen volume), HAI (alcohol activity), eFS (estimated fibrosis) and eEV (estimated varices).  These identify those at risk of adverse outcomes such as ascites, variceal bleeding, hepatic encephalopathy, and liver-related death.  Differentials of these indices indicate fatty liver, steatohepatitis (alcoholic and non-alcoholic), cirrhosis, portal hypertension, varices and infiltrative spleen disease.

HEPATIQ is cleared for sale by the FDA and the scan is covered by insurance.

Brands: HEPATIQ uses existing equipment and staff to boost radiology revenues. 1. For patients with cirrhosis, PHM indicates likelihood of liver decompensation. 2. For HCC interventions PHM indicates likelihood of liver failure. 3. For transplant candidates with low MELD scores, PHM may be used to obtain a MELD exception. 4. PHM provides an objective method of accessing efficacy of pharmacological, radiological or surgical therapies for the underlying causes of liver disease.

 Show Specials

• HEPATIQ Free Trial (Dec 03, 2022)

  We are offering new customers a six month trial of up to 50 HEPATIQ physician reports at no cost.  Let your clinical physicians know you have this capability so they will refer their liver disease patients for a liver SPECT scan (CPT 78803) which is covered by most insurance (Medicare pays approximately US$1,400).   You then use the cloud HEPATIQ software to process these images and produce the HEPATIQ report for distribution to the referring physician.  Alternatively, if you are in the USA you can skip the cloud based free trial and go straight to a paid local installation on one of your workstations. 

  HEPATIQ can dramatically boost radiology revenues.  HEPATIQ is the only test that quantifies liver function.  All of the other tests on the market (blood, elastography and biopsy) estimate the extent of liver fibrosis.  Research shows that function outperforms fibrosis in the prediction of disease outcomes.  The HEPATIQ software is cleared for sale by the FDA.

 Products